Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-11-06
2007-11-06
Chang, Celia (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
10986352
ABSTRACT:
A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for determining effective doses of new drug candidates in human populations. In addition, the high specificity, slow onset and long duration of the action of these compounds at the receptors makes them particularly well suited for therapeutic uses, for example as substitute medication for psychostimulant abuse. Some of these compounds may be useful in treating Parkinson's Disease or depression, by virtue of their inhibitory properties at monoamine transporters.
REFERENCES:
patent: 3133073 (1964-05-01), Archer
patent: 3813404 (1974-05-01), Clark
patent: 3975237 (1976-08-01), Rubenstein et al.
patent: 4041040 (1977-08-01), Christenson et al.
patent: 4179567 (1979-12-01), Clark et al.
patent: 4235864 (1980-11-01), Kaul et al.
patent: 4366154 (1982-12-01), Tomesch
patent: 5122361 (1992-06-01), Kung
patent: 5128118 (1992-07-01), Carroll et al.
patent: 5141959 (1992-08-01), Carroll et al.
patent: 5186921 (1993-02-01), Kung et al.
patent: 5262428 (1993-11-01), Davies et al.
patent: 5288872 (1994-02-01), Davies et al.
patent: 5310912 (1994-05-01), Neumeyer et al.
patent: 5374636 (1994-12-01), Moldt
patent: 5380848 (1995-01-01), Kuhar et al.
patent: 5413779 (1995-05-01), Kuhar et al.
patent: 5439666 (1995-08-01), Neumeyer et al.
patent: 5496953 (1996-03-01), Kuhar et al.
patent: 5554626 (1996-09-01), Moldt
patent: 5736123 (1998-04-01), Carroll
patent: 5831095 (1998-11-01), Gonzalez et al.
patent: 5935953 (1999-08-01), Kuhar et al.
patent: 6123917 (2000-09-01), Carroll
patent: 6329520 (2001-12-01), Carroll et al.
patent: 6358492 (2002-03-01), Kuhar et al.
patent: 6416735 (2002-07-01), Carroll et al.
patent: 6479509 (2002-11-01), Carroll
patent: 6531481 (2003-03-01), Carroll et al.
patent: 6531483 (2003-03-01), Kuhar et al.
patent: 6538010 (2003-03-01), Carroll
patent: 6552032 (2003-04-01), Carroll et al.
patent: 6559159 (2003-05-01), Carroll et al.
patent: 6593348 (2003-07-01), Carroll et al.
patent: 6706880 (2004-03-01), Carroll et al.
patent: 6900228 (2005-05-01), Carroll et al.
patent: 7011813 (2006-03-01), Kuhar et al.
patent: 2002/0132828 (2002-09-01), Carroll et al.
patent: 2002/0188003 (2002-12-01), Kuhar et al.
patent: 2003/0158415 (2003-08-01), Carroll et al.
patent: 2003/0176434 (2003-09-01), Carroll
patent: 2003/0203934 (2003-10-01), Kuhar et al.
patent: 2004/0146518 (2004-07-01), Carroll et al.
patent: 2005/0197360 (2005-09-01), Kuhar et al.
patent: WO93/09814 (1993-05-01), None
U.S. Appl. No. 11/272,492, filed Nov. 14, 2005, Carroll.
Canadian Office Action mailed dated 20, 2005.
Maarten E. A. Reith et al., “Structural Requirements for Cocaine Congeners to Interact with Dopamine and Serotonin Uptake Sites in Mouse Brain and to Induce Stereotyped Behavior”, Biochemical Pharmacology, vol. 35, No. 7, pp. 1123-1129, 1986.
Australian Office Action Dated Jan. 25, 2000, 2pp.
PCT Written Opinion Dated Jul. 24, 1998, 5pp.
Australian Patent Office Examiner's first report received in corresponding application on Feb. 4, 2003.
J. Med. Chem. (JMCMAR, 00222623), Mar. 20, 1992, vol. 35(6), pp. 969-981, XP002116827, Research Triangle Inst., Research Triangle Park, 27709, North Carolina, USA.
Nida Res. Monogr. (MIDAD4, 03618595), 1990, vol. 96 (Drugs Abuse: Chem., Pharmacol., Immunol., AIDS), pp. 112-121, XP002116828, Research Triangle Inst., Research Triangle Park, 27709, North Carolina, USA.
J. Med. Chem. (JMCMAR, 00222623), 1993, vol. 36(20), pp. 2886-2890, XP002116829, Research Triangle Inst., Research Triangle Park, 27709, North Carolina, USA.
F. Carroll, et al., “Synthesis and ligand binding of 3,beta.-(3-substituted phenyl)-and 3.beta.-(3-4-disubstituted phenyl)tropane-2.beta.-carboxylic acid methyl esters”, Med. Chem. Res. (MCREEB, 10542523), 1991, vol. 1(6), pp. 382-387, XP002116826, Research Triangle Inst., Research Triangl Park, 27709, North Carolina, USA.
J.L. Neumeyer et al., “[123I]-2β-Carbomethoxy-3β-(4-iodophenyl)tropane: High-Affinity SPECT Radiotracer of Monoamine Reuptake Siters in Brain1”, Journal of Medicinal Chemistry, vol. 34, No. 10, Oct. 1991, pp. 3144-3146.
F.I. Carroll, “Synthesis Ligand Binding, QSAR, and CoMFA study of 3β-(p-Substituted phenyl)tropane-2β-carboxylic Acid Methyl Esters”, Journal of Medicinal Chemistry, vol. 34, No. 9, Sep. 1991, pp. 2719-2725.
Chemical Abstracts, vol. 114, No. 7, Feb. 18, 1991, Abstract No. 62429c, T.M. Naseree et al., “Synthesis for tritium-labeled (3H)WIN 35, 065-02; A New Radioligand for Cocaine Receptors”.
F.I. Carroll, et al., “Isopropyl and phenyl esters of 3-beta-(4-substituted phenyl)tropan-2-beta-carboxyl acids”, Journal of Medicinal Chemistry, vol. 35, No. 16, Jun. 26, 1992, pp. 2497-2500.
Bojia, et al., “High Potency Cocaine Analogs: Neurochemical, Imaging and Behavioral Studies”, The Neurobiology of Drug and Alcohol Addiction, Annauls of the New York Academy of Sciences, vol. 654, Jun. 28, 1992.
Balaster, et al., “Potent substituted-3β-phenltropane analogs of cocaine have cocaine-like discriminative stimulus effects”, Drug and Alcohol Dependence, 29 (1991), pp. 145-151, Elsevier Scientific Publishers Ireland Ltd.
Cline, et al., “Stimulus generalization from cocaine to analogs with high in vitro affinity for dopamine uptake sites”, Behavioural Pharmacology (1992), 3, pp. 113-116 Short Report.
Cline, et al., “Behavioral Effects of Novel Cocaine Analogs: A Comparison with in Vivo Receptor Binding Potency1,2”, The Journal of Pharmocology and Experimental Therapeutics, vol. 260, No. 3, pp. 1174-1179.
Abraham Philip
Boja John W.
Carroll Frank I.
Kuhar Michael J.
Lewin Anita H.
Chang Celia
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Research Triangle Institute
LandOfFree
Cocaine receptor binding ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cocaine receptor binding ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cocaine receptor binding ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3803686